Skip to main content
Premium Trial:

Request an Annual Quote

B. Braun Takes 20 Percent Stake in German Diagnostics Firm CeGaT

Premium

CeGaT, the Center for Genomics and Transcriptomics, said this week that healthcare product and service provider B. Braun Melsungen has taken a 20 percent stake in the firm.

The investment will allow CeGaT, based in Tübingen, Germany, to further expand its range of diagnostic panels and to distribute them internationally. CeGaT did not reveal the size of the investment.

According to its website, CeGaT currently offers 55 sequencing-based diagnostic panels for a range of genetic diseases, including ALS, FTD, dementia, Parkinson's disease, dystonia, neurokanthocytosis, epilepsy and metabolic disorders, hereditary eye diseases, neuromuscular diseases, and hereditary hearing loss (IS 10/26/2010).

The company, founded in 2009, is equipped with SOLiD 5500xl and SOLiD 4 instruments, an Ion Torrent PGM, and a capillary sequencer.

This is B. Braun's first entry into the genetic diagnostic market. "With CeGaT, we are taking a stake in a young, dynamic company that is perfectly aligned for the diagnostics market, one of the large growth markets of the future," said Heinz-Walter Große, chairman of B. Braun's board, in a statement.

B. Braun, based in Melsungen, Germany, provides products and services for anesthesia, intensive medicine, cardiology, extracorporeal blood treatment, and surgery. The company has more than 43,000 employees in more than 50 countries and reported €4.4 billion ($5.8 billion) in revenues in 2010.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.